CorMedix
Open
$7.60
Prev. Close
$7.61
High
$7.60
Low
$7.58
Market Snapshot
$589.34M
3.6
-0.31
$43.47M
191
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 191 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
emptyResult
CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company is headquartered in Berkeley Heights, New Jersey and currently employs 191 full-time employees. The company went IPO on 2010-03-25. The firm is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The firm is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The firm is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
Recently from Cashu
CorMedix Reports Strong Q4 Earnings, Focuses on Innovation and Future Growth Strategies
### CorMedix Champions Innovation and Growth in Q4 Earnings CorMedix (NASDAQ: CRMD) unveils its Q4 earnings with a focus on transformative advancements in its product pipeline, aligning with the compa…
Cormedix Set to Reveal Key Insights in Upcoming Q4 Earnings Announcement
Cormedix Charts a Promising Path Ahead with Q4 Earnings Announcement As Cormedix (NASDAQ: CRMD) gears up for its quarterly earnings release on March 5, 2026, it stands at a crucial intersection betwee…
Cormedix's Promising Product Pipeline Ahead of Q4 Earnings Report Release
Cormedix's Q4 Earnings Highlight Promising Developments in Product Pipeline Cormedix (NASDAQ: CRMD) prepares to release its quarterly earnings report on March 5, 2026, a significant event that promise…
It seems you haven't provided the specific content you'd like summarized. Please share the text, and I'll be happy to help you create a concise title.
Please provide the text you would like summarized.